NeOnc Technologies Holdings, Inc.: Focused on Development of Innovative Drug De

1. Global Brachytherapy Market: Size, Share, and Growth Trends AI-Powered Cancer Research at UW-Madison Unveils New Insights into Glioblastoma Innovating Beyond THE BLOOD-BRAIN Drug Delivery Barrier for LIFE-CHANGING THERAPEUTICS, 2025 Founder & CEO NeOnc Technologies Holdings, Inc. Dr. Chen Focused on Development of Innovative Drug Delivery Solutions FOR BRAIN CANCER AND CNS TREATMENT

2. SUBSCRIBE How about showcasing your products to 90,000+ C-suite Subscribers? To get recent updates of our magazines OUR PREVIOUS EDITIONS OUR PREVIOUS EDITIONS

3. The Lifesciences Magazine, 1985, Henderson Rd, Columbus, Ohio, 43220 Follow Us On: For Editorial Concerns: editors@thelifesciencesmagazine.com For Sales & Branding Enquiries: matthew@thelifesciencesmagazine.com For Subscription: info@thelifesciencesmagazine.com Publisher Business Development Executive Rebecca Clark The Lifesciences Magazine Creative Content Editor Shalmali W. Creative Designer Paul Young Marketing Coordinator (USA) Matthew Eden Social Media Manager Amy Muller Digital Circulation Manager PR & Marketing Coordinator Michael Stevens Amanda V. This list is NOT a ranking. The companies on listed in magazine serve different aspects of the market, making ranking them in any order except revenue impossible and unfair. We try to bring a perfect platform for business organization to showcase their valued products/ services. Copyrights © The Lifesciences Magazine All Rights Reserved. The images and content included in this magazine should not be copied, transferred or reproduced in any form or by any means, electronics, mechanical, photocopying, recording, otherwise, without proper permission from The Lifesciences Magazine. The Lifesciences Magazine solely owns all the reprint rights.

4. FROM EDITOR’S DESK NeOnc Technologies Holdings, Inc. stands at the forefront of innovative medical advancements, tackling one of the most formidable challenges in neuroscience and oncology: the blood-brain barrier (BBB). This natural barrier, while essential for protecting the brain, has long hindered effective treatment for brain cancer and central nervous system (CNS) diseases. With its revolutionary NEO-100 intranasal delivery platform, NeOnc Technologies is rewriting the narrative, offering hope to patients with limited treatment options. NeOnc Technologies was founded on the visionary work of Dr. Chen, Founder, and Scientist, oncology and neuroscience whose deep expertise in of medicine’s greatest challenges: delivering effective therapies across the blood-brain barrier. led to a mission to solve one Founded on the groundbreaking work of Dr. Chen, a visionary scientist and oncologist, Dr. Chen's extensive research at USC Keck Medical School laid the foundation for the company’s innovative approach, addressing unmet needs in CNS and brain cancer treatment. At the core of NeOnc's breakthrough is NEO-100, a development-stage platform derived from Perillyl Alcohol (POH). Delivered intranasally, NEO-100's small molecular size enables it to bypass the BBB, delivering therapeutic agents directly to the brain. This platform holds immense potential, from regulating tumor cell growth to serving as a conduit for larger therapeutic molecules. In high concentrations, NEO-100 shows promise as a standalone treatment for brain cancers, while in lower concentrations, it enhances the efficacy of traditional therapeutics. NeOnc's commitment extends beyond research, as its robust intellectual property portfolio and ongoing clinical trials underscore its dedication to delivering transformative solutions. As the company continues to innovate, it stands poised to redefine how we approach CNS treatment, offering life-changing possibilities to patients worldwide. Through relentless innovation and a patient-centered focus, NeOnc Technologies is paving the way for a future where CNS diseases are not only treatable but potentially curable. halmali S Shalmali W.

5. REDEFINING THE SCIENCE OF LIFE The Lifesciences Magazine is global healthcare solutions platform that paves the way for various healthcare innovations, advices of professionals.

6. Leaders in Spotlight NeOnc Technologies Holdings, Inc. is making waves in the life sciences industry, tackling one of the greatest challenges in modern medicine: delivering effective therapies across the blood-brain barrier (BBB). This clinical-stage company, led by a team of visionary leaders, is redefining treatment options for brain cancer and central nervous system (CNS) disorders through innovative solutions like its NEO-100 intranasal delivery platform. At the heart of NeOnc’s groundbreaking advancements is Dr. Chen, the founder and driving force behind the company’s mission. A seasoned oncologist and neuroscientist, Dr. Chen’s research at USC Keck Medical School laid the foundation for NeOnc’s cutting-edge approaches. His dedication to solving critical unmet needs for patients with CNS diseases and brain cancer has propelled NeOnc Technologies to the forefront of medical innovation. Under Dr. Chen’s leadership, the company has developed NEO-100, a proprietary platform derived from Perillyl Alcohol (POH). This development-stage technology is designed to bypass the BBB, delivering targeted therapies directly to the brain. NEO-100's versatile applications range from treating brain cancers in high concentrations to acting as a solvent for large-molecule therapeutics, enhancing their ability to cross the BBB. NeOnc’s strong intellectual property portfolio and ongoing Phase I and Phase II clinical trials underscore its commitment to transforming early-stage research into viable patient solutions. The company’s pioneering efforts are paving the way for non-invasive, precision- focused treatments, offering hope to patients who have long faced limited options. By prioritizing innovation, collaboration, and a patient-centric approach, NeOnc Technologies continues to shine as a leader in CNS therapeutics, driving a future where life-changing solutions are within reach for patients worldwide.

7. 10. COVER STORY NeOnc Technologies Holdings, Inc. contents 20. ARTICLE Revolutionizing Brain Health: Targeted CNS Therapies Advancements 24. MARKET RESEARCH REPORT Global Brachytherapy Market: Size, Share, and Growth Trends 28. ARTICLE Innovative Drug Delivery for Brain Cancer: Redening Treatment Boundaries 32. GLOBAL EVENTS Global Events for Biotechnology and Nervous System Injury and Repair 36. ARTICLE Breaking Barriers: NEO-100 Brain Cancer Therapy 40. NEWS OF THE WEEK AI-Powered Cancer Research at UW-Madison Unveils New Insights into Glioblastoma

10. Cover Story Focused on Development of Innovative Drug Delivery Solutions for Brain Cancer and CNS Treatment Dr. Chen | Founder & CEO For decades, treating brain cancer and central nervous system (CNS) disorders has been one of medicine’s toughest battles, largely because of the blood-brain barrier (BBB)—a natural defense that blocks most therapies from reaching the brain. While this barrier protects the brain, it also limits treatment options, leaving patients with few solutions and diminished hope. Today, advancements in biotechnology are changing that narrative, opening doors to non-invasive, targeted therapies that can overcome these limitations and deliver life-changing results. NeOnc Technologies Holdings, Inc., is a clinical-stage life-sciences company focused on the development of innovative solutions for how we approach CNS diseases and brain cancer. Focused on the development of its innovative NEO-100 intranasal delivery platform, NeOnc Technologies is involved in the development of a method designed to bypass the BBB so that therapies reach the brain where they are needed most. NeOnc Technologies’s commitment is to deliver hope through innovation and work towards offering solutions that are effective and life-changing. 10

11. www.thelifesciencesmagazine.com | 11

12. Cover Story The Visionary Beginnings of NeOnc Technologies Overcoming the Blood-Brain Barrier NeOnc Technologies was founded on the visionary work of Dr. Chen, Founder, and Scientist, whose deep expertise in oncology and neuroscience led to a mission to solve one of medicine’s greatest challenges: delivering effective therapies across the blood-brain barrier. Dr. Chen’s research at USC Keck Medical School highlighted the potential to address critical unmet needs for patients with CNS diseases and brain cancer. This dedication to innovation continues to drive NeOnc Technologies’s mission to develop life-changing solutions and to offer hope where few treatment options exist. The BBB presents a significant challenge for traditional therapies, as its selective nature prevents many treatments from reaching the brain in effective concentrations. This limitation has made it difficult to address brain disorders with conventional methods, reducing their overall effectiveness. NeOnc Technologies has responded to this issue with NEO-100, a development-stage platform that designed to bypasses the BBB safely, allowing therapeutic agents to reach their targets in the brain. NEO-100 is made from a proprietary synthesis of Perillyl Alcohol (POH), which research suggests may have beneficial effects for treating CNS diseases. These include. 12

13. Potentially acting as a regulator for neurological pathways associated with tumor cell growth. When delivered intranasally, its small molecular size allows it to bypass the BBB. When delivered intra- arterially, it can temporarily open the BBB, allowing larger molecule therapeutics to pass through. 1. In high concentrations, NEO-100 may be a treatment for brain cancers. In lower concentrations, it may serve as a solvent for traditional large- molecule therapeutics, potentially helping them cross the BBB. It may potentially be conjugated with other CNS therapeutics to create compound formulations that may be used to enhance BBB penetration and improve brain cancer treatment. With its first-mover advantage and a strong intellectual property portfolio protecting its innovations, NeOnc Technologies is paving the way for potential new treatment options that were once thought impossible. 3. 2. 4. www.thelifesciencesmagazine.com | 13

14. Cover Story NeOnc Technologies’s Progress in Clinical Trials NeOnc Technologies is making significant progress with its innovative therapies in clinical trials, advancing toward potential solutions for brain cancer and CNS disorders. The company’s commitment to groundbreaking research is demonstrated by ongoing Phase I and Phase II trials that are paving the way for new treatment options for patients. Intellectual Property Protection: A robust portfolio safeguarding NeOnc’s innovations. Clinical Trial Progress: Ongoing Phase I and Phase II trials, reflecting the company’s commitment to transform early- stage research into viable patient solutions. Revolutionizing CNS Treatment The Company’s development-stage NEO-100 intranasal delivery system is designed to offer a solution to CNS disorders by bypassing the BBB and delivering higher concentrations of therapeutic agents directly to the brain. Unlike traditional therapies, NEO-100 can potentially offer a non-invasive, precision-focused method for treatment of brain cancer and other CNS conditions, Expanding Drug Delivery Beyond the BBB NeOnc Technologies is focused on advancing its clinical trials and expanding the use of NEO-100 to benefit a broader range of patients. The company is also exploring new potential applications for its intranasal platform. With a strong first-mover advantage and solid intellectual property protection, the company believes it is well-positioned to offer potential solutions in the next phase of CNS therapeutics. Innovation and Regulatory Challenges in Biotech Balancing innovation with regulatory compliance requires a proactive approach. NeOnc works closely with regulatory bodies, while its strong intellectual property portfolio supports ongoing innovation. Dr. Chen’s commitment to scientific research, along with a team focused on patient outcomes, ensures that NeOnc Technologies continues to prioritize the development of transformative therapies, even when navigating complex regulatory challenges. 14

15. Amir Heshmatpour Executive Chairman www.thelifesciencesmagazine.com | 15

16. 16

17. Cover Story Advice for Life Sciences Innovators Amir’s advice is to embrace bold thinking and persistence. Overcoming barriers like the BBB requires a strong commitment to innovation and the ability to navigate challenges. He emphasizes the importance of building a strong team, fostering collaboration, and safeguarding intellectual property with a solid patent strategy. Amir’s core belief is simple: patients must always be at the heart of the mission, with the ultimate goal being to transform and improve their lives. The Future of Brain-Targeted Drug Delivery Technology The future of brain-targeted drug delivery is focused on precision, non-invasive methods, and the integration of advanced technologies. In the coming years, it is hoped that barriers like the BBB will no longer limit treatment options, opening new opportunities for patients with CNS diseases. With NEO-100, NeOnc Technologies believes it is well-positioned to drive this transformation. With its strong portfolio, the company is working toward a future where CNS diseases are treatable and potentially curable. Company’s Name: NeOnc Technologies Holdings, Inc. Headquarter: Malibu, California, United States URL: https://neonc.com/ Person Name: Dr. Chen Designation: Founder & CEO www.thelifesciencesmagazine.com | 17

20. Revolutionizing Brain Health: Targeted CNS Therapies Advancements The central nervous system (CNS), encompassing the brain and spinal cord, is a complex and intricate network that governs every aspect of our being. From our thoughts and emotions to our movements and senses, the CNS orchestrates the symphony of life. However, a myriad of neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke, can disrupt this delicate balance, leading to debilitating conditions. Fortunately, the field of neuroscience is witnessing a surge of innovation, with targeted CNS therapies advancements emerging as a beacon of hope. These therapies aim to address the root causes of neurological diseases with unprecedented precision, offering the potential for more effective and personalized treatments. can be designed to target specific cell types or regions within the brain. to the affected areas, minimizing off- target effects. Some of the promising approaches include: Gene Therapy: This approach involves delivering genetic material to specific cells within the CNS to correct genetic defects or introduce therapeutic genes. Viral vectors, such as adeno-associated viruses (AAVs), are commonly used to deliver these genetic payloads. Immunotherapy: This approach harnesses the power of the immune system to target and eliminate diseased cells or proteins. Immunotherapies for neurological diseases, such as checkpoint inhibitors and CAR T-cell therapies, are currently under investigation. Overcoming the Challenges of the Blood-Brain Barrier One of the major hurdles in developing effective CNS therapies is the blood-brain barrier (BBB). This protective shield safeguards the brain from harmful substances but also hinders the entry of many therapeutic drugs. Researchers are actively exploring innovative strategies to circumvent this barrier, including: Focused Ultrasound: This non-invasive technique can temporarily open the BBB, allowing drugs to more readily enter the brain. Cell-Based Therapies: Stem cell therapies show promise in regenerating damaged neurons and glial cells. Researchers are exploring the use of stem cells to replace lost neurons or to deliver therapeutic genes. Precision Targeting: A New Era of CNS Therapies Traditional CNS therapies often have limited specificity, affecting multiple brain regions and leading to unwanted side effects. Targeted therapies, however, aim to deliver therapeutic agents directly Nanotechnology: Nanoparticles can be engineered to encapsulate drugs, allowing them to traverse the BBB more effectively. These nanoparticles Neurotrophic Factors: These proteins play a crucial role in neuronal growth and survival. Targeted delivery of 20

21. areas hold the promise of transforming the treatment of neurological diseases. Some of the key areas of focus include: Personalized Medicine: Tailoring treatments to individual patients based on their genetic makeup, disease stage, and other factors. Combination Therapies: Combining multiple therapeutic approaches to achieve synergistic effects. Disease Modification: Developing therapies that can not only alleviate symptoms but also slow or halt disease progression. Neuroprotection: Protecting vulnerable neurons from damage and promoting their repair. Targeted CNS therapies advancements represent a paradigm shift in the treatment of neurological diseases. By addressing the root causes of these conditions with unprecedented precision, these therapies offer the potential for more effective and personalized treatments. As research continues to advance, we can anticipate a future where neurological diseases are no longer insurmountable challenges, but rather manageable conditions. neurotrophic factors can promote neuronal repair and regeneration. deliver therapeutic genes to specific cell types within the CNS. Advancements in Drug Delivery Systems The Role of Artificial Intelligence (AI) in CNS Drug Discovery Delivering drugs to the CNS remains a significant challenge. However, advancements in drug delivery systems are paving the way for more effective and targeted therapies. These include: AI is revolutionizing the field of drug discovery, including the development of CNS therapies. AI algorithms can analyze vast datasets to identify novel drug targets, predict drug-target interactions, and accelerate the drug development process. Moreover, AI- powered tools can help personalize treatment plans by analyzing individual patient data, such as genetic information and imaging data. Conclusion Ultimately, the future of CNS therapies lies in personalized medicine. By leveraging AI and other technologies, researchers can tailor treatments to the unique needs of each patient, maximizing efficacy and minimizing side effects. This personalized approach, coupled with ongoing advancements in drug delivery and disease modification strategies, holds the key to unlocking the full potential of targeted CNS therapies and transforming the lives Implantable Pumps: These devices can continuously deliver drugs directly to the brain, providing sustained therapeutic levels. Convection-Enhanced Delivery (CED): This technique uses pressure to deliver drugs directly to the brain parenchyma, bypassing the BBB. The Future of Targeted CNS Therapies Advancements The future of targeted CNS therapies advancements is bright. Continued research and development in these Viral Vectors: As mentioned earlier, viral vectors can be engineered to www.thelifesciencesmagazine.com | 21

24. Global BRACHYTHERAPY MARKET (Size, Share, and Growth Trends) The global brachytherapy market is experiencing significant growth, driven by the increasing prevalence of cancer, technological advancements, and a rising adoption of minimally invasive treatments. Brachytherapy, a form of radiation therapy where radioactive sources are placed inside or near tumors, offers targeted treatment with minimal impact on surrounding healthy tissues. Table of Contents Market Size and Growth As of 2023, the global brachytherapy market was valued at approximately USD 0.95 billion and is projected to reach USD 1.50 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 7.25% from 2024 to 2031. 1. Executive Summary 2. Market Introduction 3. Research Methodology Key Market Drivers 4. Market Dynamics Rising Cancer Incidence: 5. Market Factor Analysis The increasing global cancer burden is a primary driver for the brachytherapy market. The growing number of cancer cases worldwide necessitates effective treatment options like brachytherapy. 6. Global Brachytherapy Market, By Technology 7. Global Brachytherapy Market, By Type of Brachytherapy Technological Advancements: Innovations such as 3D-brachytherapy and image- guided brachytherapy have enhanced treatment precision, leading to better patient outcomes and increased adoption of brachytherapy procedures. 8. Global Brachytherapy Market, By Application 9. Global Brachytherapy Market, By End User Preference for Minimally Invasive Treatments: 10. Global Brachytherapy Market, By Region Brachytherapy’s minimally invasive nature results in shorter recovery times and fewer side effects compared to traditional treatments, making it a preferred option among patients and healthcare providers. 11. Competitive Landscape 12. Company Profiles 24

25. Market Segmentation By Type: The market is segmented into High-Dose Rate (HDR) and Low-Dose Rate (LDR) brachytherapy. HDR brachytherapy is anticipated to witness substantial growth due to its shorter treatment times and effectiveness in various cancer types. By Technology: Technological segments include 3D-brachytherapy, image-guided brachytherapy, conventional brachytherapy, and others. Advancements in these technologies are improving treatment outcomes and expanding the applicability of brachytherapy. By Application: Brachytherapy is widely used for treating prostate, breast, gynecological, and other cancers. The prostate cancer segment accounted for a significant revenue share, owing to the high prevalence of the disease and the effectiveness of brachytherapy in its treatment. By End-User: Hospitals, ambulatory surgical centers, and cancer treatment centers are the primary end-users of brachytherapy services. Hospitals hold the largest market share due to the availability of advanced healthcare infrastructure and skilled professionals. Regional Insights North America: Asia-Pacific: In 2021, North America held the largest share of the global brachytherapy market, accounting for over 35% of the global revenue. This dominance is attributed to the rising cancer rates, aging population, and well-established healthcare infrastructure in the region. This region is expected to exhibit the highest CAGR during the forecast period, driven by increasing healthcare investments, rising awareness about cancer treatments, and improving healthcare facilities. www.thelifesciencesmagazine.com | 25

26. Competitive Landscape The brachytherapy market is characterized by the presence of several key players focusing on product innovation and strategic collaborations to strengthen their market position. Some prominent companies include: Argon Medical Elekta AB Becton, Dickinson and Company IsoRay, Inc. Eckert & Ziegler BEBIG iCAD, Inc. Future Outlook The brachytherapy market is poised for substantial growth, driven by continuous technological advancements, increasing cancer prevalence, and a growing preference for minimally invasive treatment options. Ongoing research and development efforts are expected to further enhance the efficacy and application scope of brachytherapy, solidifying its role in cancer care 1 Which is the leading segment in the Global Brachytherapy Market? Hospitals lead the market among end-users due to their ability to address a broader spectrum of medical specialties and handle a significantly higher patient volume. 2 What are the key factors driving the Global Brachytherapy Market? The market growth is primarily driven by the rising prevalence of cancer, a shift toward outpatient surgical procedures, reduced side effects with shorter treatment durations, and increasing demand for minimally invasive treatment options. 3 Which region is expected to significantly contribute to the Global Brachytherapy Market? North America is anticipated to account for the largest share, making a significant contribution to market growth. 26

28. Brain cancer is one of the most challenging areas of oncology. Its complexities go beyond just the biology of tumors; the brain's natural defense mechanism, the blood-brain barrier (BBB), presents a formidable obstacle to effective treatment. However, advancements in drug delivery systems are opening new possibilities, promising a transformative shift in how we approach brain cancer therapy. The Challenge of the Innovative Drug Delivery for Brain Cancer The blood-brain barrier is a highly selective membrane that shields the brain from harmful substances in the bloodstream. While this barrier is essential for protecting the brain, it also prevents most therapeutic agents from penetrating and reaching their intended targets. Traditional treatments, including chemotherapy and biologics, often fail to deliver adequate drug concentrations to the brain, resulting in limited effectiveness and high systemic toxicity. For decades, the inability to bypass the BBB has restricted innovation in brain cancer treatments. The challenge lies not only in crossing the barrier but also in delivering the therapy precisely to cancerous cells while sparing healthy tissue. 28

29. 4. Convection-Enhanced Delivery (CED) Revolutionizing Innovative Drug Delivery for Brain Cancer CED involves directly infusing drugs into the brain tissue using microcatheters. This technique bypasses the BBB altogether and ensures high local drug concentrations. Recent advancements in biotechnology and material science are overcoming these challenges, introducing Innovative drug delivery for brain cancer mechanisms that promise to redefine brain cancer treatment. These technologies aim to enhance the bioavailability of drugs in the brain, minimize side effects, and improve patient outcomes. Here are some of the most promising approaches: Advantages: Precise targeting, minimal systemic toxicity, and the ability to deliver large molecules. Ÿ Challenges: Invasive nature and the need for careful monitoring. Ÿ 1. Nanotechnology-Based Drug Delivery 5. Gene and Cell Therapy Nanoparticles have emerged as a game-changing tool in oncology. These tiny, engineered particles can be designed to carry therapeutic agents across the BBB. Functionalized nanoparticles can be coated with ligands that target specific receptors on the barrier, allowing them to ferry drugs directly to tumor cells. Innovative genetic approaches, such as CRISPR-Cas9 and viral vectors, are being used to reprogram cells or deliver therapeutic genes directly to tumor sites. These therapies can modulate the tumor microenvironment or enhance immune responses. Advantages: Long-lasting effects, potential to target the root cause of cancer, and synergy with other therapies. Ÿ Advantages: High precision, reduced systemic toxicity, and the ability to deliver a combination of drugs. Ÿ Examples: Liposomes, dendrimers, and polymeric nanoparticles are being explored for delivering chemotherapeutic agents and genetic materials to brain tumors. Ÿ Examples: Oncolytic viruses and engineered CAR-T cells are under investigation for glioblastoma treatment. Ÿ The Role of NEO-100 in Transforming Brain Cancer Therapy 2. Intranasal Drug Delivery The intranasal route bypasses the BBB by utilizing the olfactory and trigeminal nerve pathways. This non-invasive method allows direct drug delivery to the brain, reducing systemic exposure. One of the most promising advancements in innovative drug delivery for brain cancer is the development of NEO- 100, an intranasal platform based on perillyl alcohol. This innovative therapy exemplifies the potential of targeted, non-invasive treatments for brain cancer. Advantages: Quick absorption, patient-friendly application, and reduced side effects. Ÿ How NEO-100 Works Examples: NEO-100, a perillyl alcohol-based therapy, exemplifies the potential of this approach in treating glioblastoma and other CNS diseases. Ÿ NEO-100 leverages the intranasal route to bypass the BBB. Its small molecular structure allows it to reach the brain directly, delivering therapeutic concentrations to the tumor site. Derived from a natural monoterpene, perillyl alcohol, NEO-100 has shown anti-cancer properties, including the ability to modulate pathways associated with tumor growth and survival. 3. Focused Ultrasound (FUS) FUS uses sound waves to temporarily disrupt the BBB, enabling the targeted delivery of therapeutic agents. Combined with microbubbles, this technique enhances drug permeability at the tumor site. Applications: Glioblastoma multiforme, one of the deadliest brain cancers, is a primary target for NEO-100. Research also suggests its potential in addressing other CNS diseases. Advantages: Non-invasive, precise, and temporary BBB opening without permanent damage. Ÿ Clinical Trials: Early-phase clinical trials have demonstrated NEO-100’s safety and efficacy, paving the way for further development and regulatory approval. Examples: Studies have shown FUS's potential in delivering antibodies and chemotherapy to glioblastoma cells. Ÿ www.thelifesciencesmagazine.com | 29

30. Challenges and Opportunities The Future of Brain Cancer Treatment While these advancements are promising, they come with their own set of challenges. Regulatory hurdles, high development costs, and the complexity of clinical trials for brain cancer therapies remain significant obstacles. However, the opportunities far outweigh these challenges: The future of brain cancer therapy lies in the convergence of technology, biology, and precision medicine. Innovative drug delivery for brain cancer systems are not just about overcoming the BBB; they represent a paradigm shift in how we approach cancer treatment—one that prioritizes patient quality of life and long-term outcomes. As research continues, therapies like NEO-100 highlight the importance of innovation in addressing critical unmet needs. These advancements give hope to patients and families, offering new possibilities where few existed before. Personalized Medicine: Advances in genomics and biomarkers enable tailored treatments that align with individual patient profiles. 1. Conclusion Collaborative Research: Partnerships between academic institutions, biotech companies, and regulatory bodies can accelerate innovation. 2. Innovative drug delivery for brain cancer systems are revolutionizing the treatment landscape for brain cancer. By overcoming the challenges of the blood-brain barrier, these technologies are opening new frontiers in oncology. NEO-100 and similar advancements underscore the transformative potential of these approaches, providing hope for better outcomes and a brighter future for those battling brain cancer. As we stand on the cusp of this new era, the commitment to innovation and collaboration will be the key to unlocking these possibilities. Integration of AI: Artificial intelligence can enhance drug discovery, optimize delivery systems, and improve clinical trial efficiency. 3. 30

32. NeuroMuscular Neurology Society Annual Meeting The NeuroMuscular Neurology Society (NMN) Annual Meeting is a premier event for healthcare professionals, researchers, and educators focusing on neuromuscular disorders. This event serves as a vital platform for sharing groundbreaking research, innovative therapies, and clinical advancements in neurology. Attendees have the opportunity to explore the latest findings in diagnostics and treatment strategies for neuromuscular diseases, as well as network with peers from around the globe. The meeting includes keynote presentations, interactive workshops, and poster sessions, providing a comprehensive learning experience. The event is designed to foster collaboration and inspire future research initiatives in neuromuscular medicine. Date: 9th-10th May, 2025 Location: Vienna, Austria Website: NMN Society Society for Neuro-Oncology Pediatric Section Meeting Dedicated to advancing pediatric neuro- oncology, the Society for Neuro-Oncology (SNO) Pediatric Section Meeting offers a unique platform for clinicians and researchers to present the latest advancements in treating and understanding pediatric brain and spinal cord tumors. The event features plenary sessions, panel discussions, and interactive workshops, focusing on innovative treatment modalities, survivorship, and supportive care. This meeting serves as a key gathering for the global pediatric neuro-oncology community, emphasizing collaboration and the exchange of ideas to improve outcomes for young patients. Date: 15th-17th May, 2025 Location: San Diego, California Website: SNO Pediatric Section 32

33. Brain Tumor Epidemiology Consortium (BTEC) Meeting 2025 The Brain Tumor Epidemiology Consortium (BTEC) Meeting is a globally recognized event bringing together researchers and professionals dedicated to understanding the epidemiological factors behind brain tumor development. This multidisciplinary conference features presentations on environmental, genetic, and lifestyle factors influencing brain tumor etiology, with an emphasis on collaboration between scientists from diverse fields. The 2025 meeting promises engaging discussions, networking opportunities, and sessions aimed at fostering new research collaborations to address the causes and prevention of brain tumors. Date: 16-18 June, 2025 Location: Los Angeles, California, USA Website: BTEC 2025 Asian Society for Neuro-Oncology Annual Meeting The Asian Society for Neuro-Oncology (ASNO) Annual Meeting is a significant event that unites neuro-oncology professionals from Asia and beyond. This gathering emphasizes the latest clinical and scientific advancements in the diagnosis, treatment, and management of brain tumors and other neurological malignancies. The meeting features keynote speeches, plenary sessions, and case-based discussions, providing attendees with insights into cutting-edge research and innovative treatment strategies. ASNO also promotes collaborations across countries to address region-specific challenges in neuro-oncology care. Date: May 26 – June 1, 2025 Location: Shanghai, China Website: ASNO Annual Meeting These events represent critical opportunities for professionals in neuro-oncology and related fields to exchange knowledge, drive research, and enhance patient care outcomes globally. www.thelifesciencesmagazine.com | 33

36. Breaking Barriers: NEO-100 Brain Cancer Therapy Brain cancer remains one of the most challenging diagnoses in modern medicine. The complexities of the brain, coupled with the protective yet restrictive nature of the blood-brain barrier (BBB), have long hindered effective treatments. However, NEO-100 Brain Cancer Therapy developed by NeOnc Technologies Holdings, Inc., is breaking new ground in the fight against this formidable disease. Understanding the Blood-Brain Barrier (BBB) Key Features of NEO-100 Brain Cancer Therapy Non-Invasive Delivery: NEO-100’s intranasal delivery system offers a non-invasive alternative to traditional methods, minimizing discomfort and reducing risks associated with invasive procedures. The BBB is a highly selective barrier that protects the brain from harmful substances. While this biological mechanism is vital for maintaining brain health, it also limits the delivery of most therapeutic agents to the brain, making it a significant obstacle in treating brain- related conditions, including cancer. Conventional therapies often fail to achieve effective concentrations in the brain, leaving patients with limited options and suboptimal outcomes. 1. Direct Brain Targeting: By bypassing the BBB, NEO-100 Brain Cancer Therapy ensures that therapeutic agents reach their intended targets in the brain, enhancing treatment efficacy. 2. Versatility: In high concentrations, NEO-100 may serve as a standalone treatment for brain cancer. In lower concentrations, it can act as a solvent for large-molecule therapeutics, facilitating their penetration across the BBB. 3. Introducing NEO-100: A Game-Changer in CNS Treatment Potential for Combination Therapies: NEO-100 can be conjugated with other CNS therapeutics to create compound formulations, potentially improving outcomes for brain cancer patients. 4. NEO-100 Brain Cancer Therapy is a cutting-edge intranasal delivery platform designed to bypass the BBB, delivering therapeutic agents directly to the brain. Derived from Perillyl Alcohol (POH), a naturally occurring monoterpene, NEO-100 has been shown to possess unique properties that make it highly effective in targeting brain tumors. Its small molecular size and innovative delivery method enable it to overcome the BBB's limitations, bringing hope to patients with brain cancer and central nervous system (CNS) disorders. The Science Behind NEO-100 NEO-100 Brain Cancer Therapy is synthesized from POH, a compound with demonstrated anticancer properties. Research suggests that POH may regulate neurological pathways associated with tumor cell growth, making it a promising candidate for brain cancer treatment. When delivered intranasally, NEO-100’s molecular properties allow it to bypass the BBB efficiently, targeting brain tumors directly and with precision. 36

37. Mechanisms of Action regulatory approval and widespread adoption is not without challenges. Navigating complex regulatory landscapes, ensuring consistent manufacturing quality, and addressing the unique needs of diverse patient populations are critical steps in bringing this therapy to market. NeOnc Technologies remains committed to overcoming these challenges, driven by its mission to transform patient outcomes. Tumor Growth Regulation: NEO-100’s active ingredient has shown potential in regulating pathways that influence tumor cell proliferation. 1. Enhanced Therapeutic Delivery: By temporarily opening the BBB when delivered intra-arterially, NEO- 100 allows larger therapeutic molecules to reach the brain. 2. Future Directions Synergistic Effects: When used in combination with other CNS therapeutics, NEO-100 may enhance their effectiveness by improving BBB penetration and therapeutic delivery. 3. Expanding Clinical Trials: NeOnc Technologies aims to advance NEO-100 through further clinical trials, exploring its efficacy across a broader range of CNS conditions. • Clinical Progress and Potential Impact Collaborative Research: Partnering with academic institutions and industry leaders to refine and expand the applications of NEO-100. • NeOnc Technologies has made significant strides in advancing NEO-100 Brain Cancer Therapy through clinical trials. Current Phase I and Phase II trials are evaluating its safety and efficacy, with promising results that highlight its potential to revolutionize brain cancer treatment. Global Accessibility: Ensuring that NEO-100 is accessible to patients worldwide, regardless of geographic or economic barriers. • Promising Outcomes A Vision of Hope Improved Drug Delivery: NEO-100 Brain Cancer Therapy has demonstrated the ability to deliver higher concentrations of therapeutic agents directly to the brain, overcoming one of the biggest challenges in CNS treatment. • The development of NEO-100 represents more than just a scientific breakthrough; it embodies a vision of hope for patients and families affected by brain cancer and CNS disorders. By addressing the limitations of conventional therapies and opening new possibilities for treatment, NEO-100 is setting a new benchmark in precision medicine. Increased Patient Comfort: The non-invasive intranasal delivery method reduces the need for surgical interventions, improving the overall patient experience. • Potential for Expanded Applications: Beyond brain cancer, NEO-100’s platform may have applications in treating other CNS disorders, broadening its impact in the field of neuroscience. • Conclusion NEO-100 Brain Cancer Therapy is poised to redefine the landscape of brain cancer therapy. Its innovative approach, backed by rigorous science and a commitment to patient-centered care, offers a beacon of hope in a field where advancements are desperately needed. As NeOnc Technologies continues to push the boundaries of what is possible, NEO-100 stands as a testament to the power of innovation in transforming lives. The future of brain cancer treatment is brighter than ever, thanks to this groundbreaking therapy. The Competitive Edge: First-Mover Advantage NEO-100’s innovative approach gives NeOnc Technologies a strong first-mover advantage in the field of brain-targeted drug delivery. With a robust intellectual property portfolio protecting its innovations, the company is well-positioned to lead the next wave of advancements in CNS therapeutics. This pioneering work not only highlights the potential of NEO-100 but also sets a new standard for addressing the challenges of brain cancer treatment. Challenges and the Road Ahead While NEO-100 holds immense promise, the journey to www.thelifesciencesmagazine.com | 37

40. AI-Powered Cancer Research at UW-Madison Unveils New Insights into Glioblastoma Professor Pallavi Tiwari’s AI Journey robust and tumor-specific insights. The AI model identified common and distinct characteristics in tumors based on the patient’s sex. Dr. Pallavi Tiwari, a professor of radiology and biomedical engineering at the University of Wisconsin-Madison, has spent 18 years advancing artificial intelligence (AI) models to revolutionize cancer research. Her work focuses on leveraging machine learning to predict cancer diagnoses, patient outcomes, and drug responses. For women, higher-risk tumors tended to invade healthy tissue, while in men, the presence of specific cells near dying tissue was associated with more aggressive tumor behavior. “These findings could guide personalized treatments, identifying the right candidates for therapies like immunotherapy or chemotherapy,” Tiwari noted. “We’ve been using AI approaches to identify overall patient outcomes and their response to specific drugs,” Tiwari explained. AI as a Medical Ally Joining UW-Madison in 2022, Tiwari leads a campus-wide AI initiative aimed at enhancing healthcare and medical imaging. Tiwari believes AI holds transformative potential for healthcare, particularly in managing vast datasets beyond human capability. AI could analyze thousands of treatment data points to determine effective therapies and their influencing factors, offering a valuable decision-support tool for oncologists. Glioblastoma Study: Insights into Sex-Based Tumor Differences Earlier this year, Tiwari and her research team investigated why glioblastoma—a lethal brain cancer—is more aggressive in men. Their findings, published in Science Advances, highlighted biological differences in how tumors develop in men versus women. “Ultimately, AI becomes an ally, helping doctors make better decisions and ensuring patients receive the most appropriate treatment,” Tiwari emphasized. This groundbreaking research not only advances cancer diagnostics but also paves the way for more personalized and effective treatment strategies. Using AI, the researchers analyzed data from 250 glioblastoma studies across various institutions to ensure 40

41. FDA Grants Priority Review to Verastem Oncology’s NDA for Recurrent Low-Grade Serous Ovarian Cancer Treatment NDA for Avutometinib and Defactinib Combination Accepted Clinical Evidence and Ongoing Trials Verastem Oncology, a biopharmaceutical company focused on innovative cancer treatments, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under the accelerated approval pathway. The NDA covers the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral FAK inhibitor, for treating adults with recurrent low-grade serous ovarian cancer (LGSOC) carrying KRAS mutations. Patients eligible for this treatment must have undergone at least one prior systemic therapy. The FDA granted Priority Review, setting a Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025, and indicated no plans for an advisory committee meeting. The NDA is supported by data from the Phase 2 RAMP 201 trial, which demonstrated substantial and durable responses in patients. The combination therapy was also well-tolerated. Additional supportive data comes from the FRAME Phase 1 trial. Verastem is conducting the Phase 3 RAMP 301 trial to further evaluate the treatment's efficacy, which could expand its indication beyond KRAS mutant cases. Addressing a Rare Cancer LGSOC primarily affects younger women, often having a profound impact on quality of life. Current treatments include chemotherapy and hormone therapy, but their efficacy is limited. Verastem’s investigational therapy represents a significant advancement for this patient population. Significance of the Approval LGSOC is a rare and persistent ovarian cancer with no FDA- approved treatments currently available. Verastem's combination therapy aims to address this significant unmet medical need. Dan Paterson, CEO of Verastem Oncology, expressed enthusiasm about the potential to deliver the first FDA-approved treatment for recurrent KRAS mutant LGSOC in the U.S., emphasizing the importance of this milestone for patients. Verastem Oncology remains committed to delivering innovative treatments, with a commercial launch expected in mid-2025, pending FDA approval. www.thelifesciencesmagazine.com | 41